A majority of the funds will go to the effort to transform medical defenses, more specifically to the development of vaccines ($24.2 billion), therapeutics ($11.8 billion), and diagnostics ($5.0 billion).
As far as no phase 3s? That's an old argument that's been beat into the ground, and has no relevance for this baby bio, strapped for funds and careful to dilute minimally, while setting up for these potentially lucrative trial results for moderate to severe Covid in hospitalized patients. All of the previous phase 2s have shown safety and indications of efficacy.
Anyone thinking Leo has diluted too much should look at other OTC companies in the same medical areas and their number of outstanding shares.